RxSight (RXST) grants major option and RSU awards to its CFO

Rhea-AI Filing Summary

RxSight, Inc. reported new equity awards to Chief Financial Officer Mark Wilterding. On January 12, 2026, he received a stock option covering 258,770 shares of common stock at an exercise price of $10.09 per share. Twenty five percent of this option vests on January 11, 2027, with the remainder vesting in equal monthly installments over the following three years, contingent on continued service.

He also received 163,528 restricted stock units, each representing one share of common stock. One eighth of the RSUs will vest on February 28, 2026, with additional one-eighth portions vesting every six months on the last day of February and August over a four-year period, also subject to his continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wilterding Mark

(Last) (First) (Middle)

100 COLUMBIA

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RxSight, Inc. [ RXST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.09	01/12/2026		A		258,770		(1)	01/11/2036	Common Stock	258,770	$0	258,770	D
Restricted Stock Unit	(2)	01/12/2026		A		163,528		(3)	(3)	Common Stock	163,528	$0	163,528	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of January 11, 2026 (the "Vesting Commencement Date"), and the remaining shares subject to the options shall vesting equally monthly on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month) over the following three years, such that all of the shares subject to the option shall be fully vested four years from the Vesting Commencement Date.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one eighth (1/8th) of the shares subject to the RSU award will vest on February 28, 2026, and one eighth (1/8th) of the shares subject to the RSU award will vest every six months thereafter on the last day of February and the last day of August over a four-year period.

	/s/ Bridget Balisy, as Attorney-in-Fact	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RxSight (RXST) report for its CFO?

RxSight reported equity awards to CFO Mark Wilterding. He received options for 258,770 shares at $10.09 per share and 163,528 restricted stock units, both subject to multi-year vesting tied to his continued service with the company.

How many stock options did RxSight (RXST) grant to its CFO and at what price?

RxSight granted CFO Mark Wilterding stock options covering 258,770 shares of common stock at an exercise price of $10.09 per share. These options vest over four years, beginning with 25% after one year and the balance vesting monthly thereafter, subject to continued service.

What are the vesting terms of the RxSight (RXST) CFO’s stock options?

The CFO’s options vest over four years. Twenty five percent vest on January 11, 2027, the one-year anniversary of the vesting commencement date, and the remaining shares vest in equal monthly installments over the next three years, contingent on continued service.

How many restricted stock units did the RxSight (RXST) CFO receive?

The CFO received 163,528 restricted stock units, each representing one share of RxSight common stock. These RSUs vest in eight equal installments over four years, beginning February 28, 2026, with further vesting every six months, subject to his continued service.

How do the RxSight (RXST) CFO’s RSUs vest over time?

One eighth of the CFO’s RSU award vests on February 28, 2026. Additional one-eighth portions vest every six months thereafter, on the last day of February and the last day of August, over a four-year period, assuming he remains a service provider.

What does each restricted stock unit represent in the RxSight (RXST) CFO grant?

Each restricted stock unit granted to the CFO represents a contingent right to receive one share of RxSight’s common stock. Delivery of shares depends on the RSUs meeting their time-based vesting schedule and his continued service to the company through each vesting date.